A Phase III, Randomised, Double-Blind, Active-controlled Study to Assess the Efficacy, Safety and Tolerability of Baxdrostat in Combination With Dapagliflozin Compared With Dapagliflozin Alone on Chronic Kidney Disease (CKD) Progression in Participants With CKD and High Blood Pressure
Latest Information Update: 08 Jun 2025
At a glance
- Drugs Baxdrostat (Primary) ; Dapagliflozin (Primary)
- Indications Hypertension; Renal failure
- Focus Registrational; Therapeutic Use
- Sponsors AstraZeneca
Most Recent Events
- 10 Jan 2025 Planned End Date changed from 10 Dec 2027 to 9 Dec 2027.
- 10 Jan 2025 Planned primary completion date changed from 10 Dec 2027 to 9 Dec 2027.
- 24 Apr 2024 Status changed from not yet recruiting to recruiting.